BioKier Biotech Secures Tens of Millions in Series A Funding to Accelerate Commercialization of Core Products, WinX Capital Acts as Exclusive Financial Advisor

Recently,Baikuirui (Shenzhen) Biotechnology Co., Ltd. (hereinafter referred to as “Baikuirui” or the “Company”) announced the completion of its Series A financing round, raising tens of millions of yuan. The round was led by Triwise Capital, with TECHNOLOGY FINANCIAL GROUP participating as a follow-on investor, and WinX Capital serving as the exclusive financial advisor.

Baikuirui is headquartered in Shenzhen. The company has established R&D and pilot-scale bases covering 3,000 square meters in both Shenzhen and Tianjin, and is actively preparing for the construction of a green bio-manufacturing facility. Dedicated to continuous innovation in biosynthetic pipelines and their industrial and commercial translation, Baikuirui focuses on personal care, pet health, and bio-pesticides. It has already forged business partnerships with leading global cosmetics and chemical enterprises.The senior management team boasts over 20 years of experience in R&D, production, and sales. Core team members are graduates from prestigious institutions specializing in biosynthesis and biomanufacturing, possessing comprehensive capabilities and extensive expertise in product selection, R&D, industrialization, and commercialization. Multiple technologies have already been implemented at an industrial scale.Leveraging its full-chain synthetic biology platform based on precise protein design and protein molecular machine technologies, Baikuirui has developed the SmartEvolution algorithm platform. By integrating protein design with AI algorithms and employing a Transformer architecture, the platform enables protein sequence design and engineering even with small-sample experimental data, achieving predictive mapping from structure to function. This significantly enhances the accuracy and development efficiency of protein and enzyme design. In the future, Baikuirui will continue to build a portfolio of high-value biosynthetic products, promoting efficient and green manufacturing of biological products.

The proceeds from this round of financing will be used to accelerate the industrialization and commercialization of Baikuiri’s leading pipeline, including targeted bactericidal proteins, anti-aging peptides, collagen, and bio-based surfactants, with a commitment to skin health and green beauty. Meanwhile, the company will continuously iterate and upgrade its existing technologies and develop more competitive synthetic biology products guided by market demand.

Protein 3D Structure

BaiKuiRui R&D Laboratory

Zhang Jiaquan, founder of Bai Kuirui Biotechnology, stated:We extend our gratitude to Triwise Capital and TECHNOLOGY FINANCIAL GROUP for their recognition and support as investors in this funding round. We also thank WinX Capital for its professional support and contributions during this financing process. Confident in BaiKuiRui’s profound understanding of the future development trends in synthetic biology, we believe the company will leverage cutting-edge technologies to address critical bottlenecks hindering traditional industries, enable high-quality green production methods, and make its due contribution to advancing China’s bio-manufacturing strategy.

Dr. Leng Xiaoyao of Triwise Capital stated:Driven by policies supporting the bioeconomy and the development of a low-carbon economy, the synthetic biology industry is witnessing a historic opportunity for growth. We place significant emphasis on investment opportunities in this sector. BaiKuiRui has established a full-chain synthetic biology platform centered on precise protein design and protein molecular machine technologies. Guided by commercialization, the company employs a reverse product selection strategy, focusing on efficient biosynthesis in areas such as skin health, biopesticides, and daily personal care products, thereby achieving cost reduction, efficiency improvement, and environmental sustainability. The founding team of BaiKuiRui represents a strong combination of scientists and entrepreneurs, boasting over two decades of technological accumulation and excellent business development capabilities. Their persistent focus on commercialization, along with an orientation toward the feasibility of technology productization and market competitiveness, are factors we view very favorably. We believe that BaiKuiRui will rapidly grow into a benchmark enterprise in the field of synthetic biology.

TECHNOLOGY FINANCIAL GROUP stated:Bai Kuirui is committed to addressing customer pain points and meeting market demands. Leveraging an advanced, efficient, and highly scalable intelligent manufacturing platform for molecular machines, the company has developed products with significant market potential, such as bactericidal proteins and biosurfactants. Several of these products have already achieved successful business and industrialization collaborations with industry leaders. The founding team possesses strong expertise in scientific research translation, production management, and industrial background. TECHNOLOGY FINANCIAL GROUP is optimistic about Bai Kuirui’s position in the synthetic biology sector, which is poised for historic growth opportunities, and expects the company to continuously deliver high-value biological products, thereby creating value for its customers and shareholders.

Dr. Zou Guowen, Founding Partner of WinX Capital, stated:We extend our sincere gratitude to Baikuairui for its trust in WinX Capital, and to both new and existing shareholders for their strong support. It is our honor to have facilitated the company’s completion of this financing round. As a key focus area of new-quality productive forces and strategic emerging industries, biomanufacturing is experiencing rapid and robust growth. We are confident that, leveraging its full-chain biosynthesis technology platform, competitive product portfolio, and the management team’s deep industry expertise, the company will swiftly bring to market a broader range of personal care, pet health, and biopesticide products with strong market potential and technological leadership, thereby becoming a significant force in the biomanufacturing sector.

Shenzhen Qianhai Triwise International Capital Management Co., Ltd. (Triwise Capital), established in October 2015, brings together senior executives from renowned venture capital firms such as Shenzhen Capital Group, industry veterans from Roche and GSK, as well as scientific experts from prestigious academic institutions both in China and abroad. Adhering to the philosophy of “redirecting investment back to the real economy and leveraging capital to serve industrial development,” Triwise Capital strategically builds an industrial ecosystem, emphasizing original and value-based investing. By integrating resources from industrial and technological platforms—including the National Innovation Center for High-Performance Medical Devices, the Institute of Synthetic Biology at the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, and the Shenzhen Jiyin Biomedical Translational Research Institute—the firm focuses on investments in cutting-edge fields such as innovative drugs, synthetic biology, and high-end medical devices. Triwise Capital engages in “co-entrepreneurship” with industrial teams, utilizing capital to accelerate the commercialization of scientific achievements. Its investment portfolio includes Akeso Inc. (09926.HK), Transwarp Technology (688031.SH), APHARMA (688176.SH), Quanxin Biotech (02509.HK), Innovent Micro Medicine, Fapon Biotech, and Northcore Life, among others. The firm has received numerous accolades, including being ranked among the “Top 30 Best Venture Capital Firms in the Guangdong-Hong Kong-Macao Greater Bay Area” by China Venture and listed among the “Top 30 VC Firms Most Favored by LPs in China” in 2023.

Guangdong Technology Financial Group Co., Ltd. (hereinafter referred to as “Technology Financial Group”) is a state-owned enterprise authorized for operation by the People’s Government of Guangdong Province. As one of the earliest venture capital institutions established in China and the country’s first provincial-level technology finance group, it is committed to building a key platform serving technological innovation in Guangdong. Technology Financial Group has received numerous honors, including the National High-Quality Investment Project Award, Top 100 Venture Capital Institutions in China’s 20-Year VC History, Global Most Promising Fund of Funds, China’s Best Venture Capital Institution, Golden Bull Award, Golden Investment Award, Golden Excellence Award, and Golden Exchange Award. To date, the group has a registered capital of RMB 10.6 billion and total assets of RMB 42.381 billion. It has established or participated in 168 funds, with a total fund size exceeding RMB 90 billion. The group has provided investment and financing services to more than 3,000 technology enterprises and facilitated the initial public offerings (IPOs) of over 180 companies.

WinX Capital is a leading investment bank in China’s healthcare sector, with headquarters in Beijing and Shanghai, covering over 3,000 active institutional investors and industrial groups. It has received numerous accolades, including being ranked No. 1 among financial advisory firms in the healthcare sector for 2022 and 2023 by First New Voice; Top 2 Best Financial Advisor in the Healthcare Sector for 2021–2022 by Qimingpian & Xinsheng Chuangfu; and Top 5 Healthcare Financial Advisor of the Year in the 2022–2023 Pengcheng Awards by VCBeat.